Ultragenyx Pharmaceutical (RARE) Other Non-Current Liabilities (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Other Non-Current Liabilities data on file, last reported at $1.1 billion in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 42.06% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 42.06% increase from a year earlier, with the FY2025 full-year figure at $44.0 million, down 94.63% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $1.1 billion, up from $44.0 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for RARE reached as high as $1.1 billion in Q1 2026 and fell as low as $3.8 million in Q2 2022.
• Historically, Other Non-Current Liabilities has averaged $387.9 million across 5 years, with a median of $44.0 million in 2025.
• Across the five-year window, Other Non-Current Liabilities sank 98.9% in 2022 and soared 21529.53% in 2023, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $4.8 million in 2022, then jumped by 17790.56% to $862.3 million in 2023, then decreased by 4.91% to $820.0 million in 2024, then plunged by 94.63% to $44.0 million in 2025, then soared by 2463.64% to $1.1 billion in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $1.1 billion in Q1 2026, $44.0 million in Q4 2025, and $18.8 million in Q3 2025.